ATOVAQUONE (atovaquone) by GSK is [see microbiology ()] . Approved for pneumocystis jirovecii pneumonia (pcp) in adults, adolescents (aged 13 years, older) and 4 more indications. First approved in 2018.
Drug data last refreshed 21h ago
[see Microbiology ()] .
Antimalarial
Worked on ATOVAQUONE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides